Advancing the Design and Manufacture of Next-Generation Therapeutics
Download this whitepaper to learn more.
Asimov is developing a synthetic biology platform applied to biologics, viral vectors, and RNA therapeutics to improve manufacturing outcomes through optimized or customized genetic sequences.
One of the biggest challenges Asimov faces is finding a partner who can supply reliable synthesis of DNA fragments for vector construction. Their solution was to turn to Elegen’s ENFINIA™ Linear DNA.
In this case study, learn how Elegen’s cell-free gene synthesis platform :
- Enabled Asimov to take advantage of immediate use of ready-made linear fragments in their plasmid assembly and the cloning pipeline, saving time and money.
- Offers US-based cell-free gene synthesis service with fast turnaround – even for complex and long sequences above 5kb in length.
- Provides long gene fragments with a higher accuracy and purity than other suppliers.
Offered Free by: Elegen